#1 Clinical Trials Search in Europe

Tamibarotene

Tamibarotene, a synthetic retinoid, is being investigated in various clinical trials for its potential in treating a range of diseases. These trials aim to evaluate the drug’s efficacy, safety, and optimal dosing in conditions such as leukemia, kidney disease, lung cancer, and neurological disorders. This article provides an overview of the ongoing research into Tamibarotene’s therapeutic applications.

Table of Contents

What is Tamibarotene?

Tamibarotene is a synthetic retinoid, which means it’s a compound related to vitamin A. It’s also known by other names such as AM80, SY-1425, and Amnolake[1]. This drug has been approved in Japan since 2005 for treating a specific type of leukemia called acute promyelocytic leukemia (APL)[2]. However, researchers are exploring its potential benefits for various other medical conditions.

Medical Conditions Treated with Tamibarotene

Tamibarotene is being studied for its effectiveness in treating several diseases:

  • Acute Myeloid Leukemia (AML): A type of blood cancer where the bone marrow makes abnormal white blood cells[3].
  • Myelodysplastic Syndromes (MDS): A group of disorders where blood cells don’t develop normally in the bone marrow[4].
  • Chronic Myelomonocytic Leukemia (CMML): A rare blood cancer that affects blood-forming cells in the bone marrow[5].
  • Lupus Nephritis: A kidney inflammation caused by systemic lupus erythematosus (SLE)[6].
  • HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP): A neurological disease caused by a virus[7].
  • Crohn’s Disease: A type of inflammatory bowel disease[8].
  • Alzheimer’s Disease: A progressive brain disorder that affects memory and thinking skills[2].
  • Non-Small Cell Lung Cancer: A common type of lung cancer[9].
  • Autosomal Dominant Polycystic Kidney Disease (ADPKD): An inherited disorder where fluid-filled cysts develop in the kidneys[10].

How Tamibarotene Works

Tamibarotene works by binding to specific receptors in the body called Retinoic Acid Receptors (RARs), particularly the alpha and beta subtypes. This interaction can have various effects on the body, including:

  • Regulating the immune system and reducing inflammation[2].
  • Promoting the development of normal blood cells in certain blood cancers[3].
  • Potentially reducing the formation of abnormal proteins in the brain associated with Alzheimer’s disease[2].
  • Possibly helping with nerve cell regeneration in some neurological conditions[2].

Administration and Dosage

Tamibarotene is typically taken orally in tablet form. The dosage and schedule can vary depending on the condition being treated and the specific clinical trial. Some common dosing regimens include:

  • 6 mg twice daily for blood cancers like AML[3].
  • 4 mg daily for conditions like lupus nephritis[6].
  • 2 mg daily, increasing to 4 mg daily for neurological conditions like HAM/TSP[7].

It’s important to note that the dosage should always be determined by a healthcare professional based on the individual patient’s condition and response to treatment.

Ongoing Research and Clinical Trials

Tamibarotene is currently being studied in various clinical trials to determine its effectiveness and safety for different conditions. Some notable ongoing research includes:

  • A study combining Tamibarotene with other drugs (venetoclax and azacitidine) for treating newly diagnosed AML in patients who can’t receive standard chemotherapy[3].
  • A trial testing Tamibarotene with azacitidine for higher-risk myelodysplastic syndromes[4].
  • Research on Tamibarotene’s potential benefits for ADPKD[10].

Potential Side Effects

Like all medications, Tamibarotene can cause side effects. While the specific side effects can vary depending on the condition being treated and individual factors, some potential side effects may include:

  • Skin irritation or dryness
  • Headache
  • Nausea
  • Fatigue

It’s important to note that the side effects of Tamibarotene are generally reported to be similar to those of other retinoid drugs[2]. However, as with any medication, patients should discuss potential risks and benefits with their healthcare provider.

Aspect Details
Drug Name Tamibarotene (also known as AM80)
Drug Class Synthetic retinoid
Primary Conditions Studied Acute Myeloid Leukemia (AML), Autosomal Dominant Polycystic Kidney Disease (ADPKD), Non-Small Cell Lung Cancer, Alzheimer’s Disease, Chronic Myelomonocytic Leukemia (CMML)
Administration Method Oral tablets
Dosage Range 2 mg to 6 mg per day, often divided into two doses
Key Outcome Measures Progression-free survival, Complete response rate, Changes in kidney volume, Cognitive function scores, Safety and tolerability
Combination Therapies Often studied in combination with other drugs such as azacitidine and venetoclax for certain conditions
Trial Phases Ranging from Phase I to Phase III, depending on the condition and study
Notable Characteristics Higher receptor selectivity and activity compared to other retinoids, potential for treating a diverse range of conditions

FAQ

  • What is Tamibarotene? Tamibarotene is a synthetic retinoid drug that is being studied for its potential to treat various diseases. It has a higher activity and receptor selectivity compared to other retinoid drugs, particularly towards certain subtypes of Retinoic Acid Receptors.
  • What conditions is Tamibarotene being studied for? Tamibarotene is being investigated for several conditions including acute myeloid leukemia (AML), autosomal dominant polycystic kidney disease (ADPKD), non-small cell lung cancer, Alzheimer's disease, and chronic myelomonocytic leukemia (CMML), among others.
  • How is Tamibarotene administered in these trials? In most trials, Tamibarotene is administered orally in tablet form. The dosage and frequency vary depending on the specific trial and condition being studied, ranging from 2 mg to 6 mg per day, often divided into two doses.
  • What are some potential side effects of Tamibarotene? While specific side effects can vary, Tamibarotene's side effects are generally reported to be similar to those of other clinically used retinoids. The trials are designed to monitor and evaluate the safety profile of the drug in different patient populations.
  • How long do these clinical trials typically last? The duration of the trials varies depending on the study design and condition being treated. Some trials last for several months (e.g., 24 weeks), while others may continue for over a year to assess long-term efficacy and safety.

Ongoing Clinical Trials on Tamibarotene

  • Study of SY-1425 (tamibarotene) alone or with azacitidine in adult patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of Tamibarotene, Venetoclax, and Azacitidine for Adults with RARA-positive Acute Myeloid Leukemia Not Eligible for Standard Therapy

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of Tamibarotene and Azacitidine Treatment in Newly Diagnosed Adults with RARA-positive Higher-risk Myelodysplastic Syndrome (MDS)

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia France Germany Hungary +3

Glossary

  • Retinoid: A class of compounds chemically related to vitamin A that can regulate gene expression and cell differentiation.
  • Retinoic Acid Receptor (RAR): A type of nuclear receptor that is activated by retinoic acid, playing a role in cell growth, differentiation, and death.
  • Acute Myeloid Leukemia (AML): A type of cancer that affects the blood and bone marrow, characterized by rapid growth of abnormal white blood cells.
  • Autosomal Dominant Polycystic Kidney Disease (ADPKD): A genetic disorder characterized by the growth of numerous cysts in the kidneys, leading to kidney enlargement and potential failure.
  • Chronic Myelomonocytic Leukemia (CMML): A type of blood cancer that affects blood-forming cells in the bone marrow, leading to an increase in monocytes in the blood.
  • Progression-free survival: The length of time during and after treatment that a patient lives with the disease without it worsening.
  • Complete Response (CR): In cancer treatment, this refers to the disappearance of all signs of cancer in response to treatment.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Total Kidney Volume (TKV): A measure of kidney size used to assess the progression of polycystic kidney disease.
  • Adverse Event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.

References

  1. https://clinicaltrials.gov/study/NCT00520208
  2. https://clinicaltrials.gov/study/NCT01120002
  3. https://clinicaltrials.eu/trial/study-of-tamibarotene-venetoclax-and-azacitidine-for-adults-with-rara-positive-acute-myeloid-leukemia-not-eligible-for-standard-therapy/
  4. https://clinicaltrials.eu/trial/study-of-tamibarotene-and-azacitidine-for-adults-with-newly-diagnosed-rara-positive-higher-risk-myelodysplastic-syndrome/
  5. https://clinicaltrials.gov/study/NCT06085638
  6. https://clinicaltrials.gov/study/NCT01226147
  7. https://clinicaltrials.gov/study/NCT01343355
  8. https://clinicaltrials.gov/study/NCT00417391
  9. https://clinicaltrials.gov/study/NCT01337154
  10. https://clinicaltrials.gov/study/NCT06289998